[ORGANIZATION]
Rasonque
Featured in 6 tracked stories · first seen
Situations
Daraxonrasib development for pancreatic cancer
3 clusters · 49 sources · last updated
Latest: ESMO 2026 Congress presents breakthrough cancer treatment results
In September 2026, Felice Antonio Spaccavento, a health official in the Puglia region of Italy, formally requested that the Italian Medicines Agency (AIFA) accelerate access to the targeted therapy daraxonrasib. The requ
FDA approves Rasonque; EMA recommends for pancreatic cancer
44 clusters · 321 sources · last updated
Latest: Pancreatic cancer: New research and treatment developments in Greece
On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed as Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDAC). Developed by R
Also covered in
-
Revolution Medicines receives FDA approval for Rasonque
[HEALTH] · 2 sources ·
-
FDA approves Rasonque for metastatic pancreatic cancer
[HEALTH] · 6 sources ·